Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Julie Baran"'
Autor:
Naomi J. Winick, Leanne Embry, Eric Larsen, Lisa M. Jacola, Julie Baran, John A. Kairalla, Stephanie E. Hullmann, Victoria W. Willard, Kristina K. Hardy, Robert B. Noll
Publikováno v:
Pediatr Blood Cancer
PURPOSE: To characterize academic and adaptive skill outcomes in survivors of high-risk B-lineage acute lymphoblastic leukemia (HR B-ALL). METHODS: Participants were 178 patients enrolled on a non-therapeutic clinical trial that aimed to characterize
Autor:
Nikita Saoji, Jeanette M. Trauth, Julie Baran, Robert B. Noll, Kathryn Vannatta, Cynthia A. Gerhardt, David Rotter
Publikováno v:
Journal of Psychoeducational Assessment. 37:566-577
The Children’s Depression Inventory (CDI) is used to screen for depression in children aged 7 years to 16 years. The purpose of this study is to examine the psychometrics of the CDI in a sample of children who are chronically ill ( N = 350) and in
Publikováno v:
Current Physical Medicine and Rehabilitation Reports. 6:107-114
With increasing survival rates in pediatric oncology, more attention has been paid to improving physical, cognitive, and psychosocial functioning for individuals on and off of treatment. We highlight the need for a multidisciplinary approach in provi
Autor:
Michael Fisher, Wendy L. Hobbie, Matthew C. Hocking, Emily K. Shabason, Julie Baran, Jane E. Minturn, Jill P. Ginsberg, Lee Isaac, Nathan J. Blum, Cole Brodsky
Publikováno v:
Journal of neuro-oncology. 143(2)
Survivors of pediatric brain tumors often have neurodevelopmental late effects, such as inattention. Symptoms may mirror those of attention-deficit/hyperactivity disorder (ADHD), which affects ~ 5–8% of the general population. This retrospective st
Autor:
Stephanie E. Hullmann, Julie Baran, Nikita Saoji, Leanne Embry, Naomi J. Winick, Robert B. Noll, Lisa M. Jacola, Kristina K. Hardy, Victoria W. Willard, John A. Kairalla
Publikováno v:
Blood. 128:4770-4770
Continuous advancement in treatment strategies for childhood acute lymphoblastic leukemia (ALL) have improved survival rates markedly over the past decades. The overall 5-year survival rate is now approaches 90% for survivors treated with contemporar